Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
hypoxia/infarction
Krækjan er vistuð á klemmuspjaldið
Bls 1 frá 34 niðurstöður
Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
Cardiovascular diseases are a leading cause of death resulting in almost 40% of deaths annually in the United States. Inadequate human myocardial regeneration poses a significant public health problem. It is estimated that 13 million Americans have coronary artery
MAPC treatment of brain injuries and diseases
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION
The field of the invention is treatment of brain injury, disorder, dysfunction, and disease using multipotent adult progenitor cells ("MAPCs"), in particular the treatment of hypoxic and ischemic brain injuries, including but not limited to Hypoxic-Ischemic Brain Injury and
Methods of intravenous administration of glyburide
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION
This invention relates to the field of medical treatment methods, including intravenous methods of administration of drugs to a subject.
BACKGROUND
Glyburide (also known as, e.g., glibenclamide) is a sulfonylurea drug used in treating diabetes. The systematic name of glyburide
Methods of intravenous administration of glyburide
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION
This invention relates to the field of medical treatment methods, including intravenous methods of administration of drugs to a subject.
BACKGROUND
Glyburide (also known as, e.g., glibenclamide) is a sulfonylurea drug used in treating diabetes. The systematic name of glyburide
Methods of intravenous administration of glyburide
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION
This invention relates to the field of medical treatment methods, including intravenous methods of administration of drugs to a subject.
BACKGROUND
Glyburide (also known as, e.g., glibenclamide) is a sulfonylurea drug used in treating diabetes. The systematic name of glyburide
Prodrug salts
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
Prodrug salts
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
The present invention relates to a health food/dietary supplement comprising as its characterising ingredients an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts or
Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
The present invention relates to a health food/dietary supplement comprising as its characterising ingredients an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts or
Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-dione type. The fused ring system is substituted at the a- or b-position by amino acid derivatives. The compounds are active as excitatory amino
Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a- or b-position by amino acid derivatives. The compounds are active as excitatory amino
Substituted quinoxaline-2-ones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the substituted quinoxaline 2-ones type. The compounds are active as excitatory amino acid receptor antagonists acting at glutamate receptors, including either or both
Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
The present invention concerns novel sulfonamide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by sulfonamide derivatives. The
Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a or b position by amino acid derivatives. The compounds are active as excitatory amino
Protein S protects the nervous system from injury
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention relates to the use of protein S and/or variants thereof as neuroprotective agents for treating brain disorders and other pathological conditions. The ability of protein S and variants thereof to act as cell survival factors on cells of the nervous systems
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
- Virkar á 55 tungumálum
- Jurtalækningar studdir af vísindum
- Jurtaviðurkenning eftir ímynd
- Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
- Lestu vísindarit sem tengjast leit þinni
- Leitaðu að lækningajurtum eftir áhrifum þeirra
- Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum
